Supplementary Protocol S1 from A Phase II Study of Abemaciclib for Patients with Retinoblastoma-Positive, Metastatic Triple-Negative Breast Cancer

This publication has 15 references indexed in Scilit:

• Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib
  Cancer Cell, 2017
• Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer
  Clinical Cancer Research, 2015
• The history and future of targeting cyclin-dependent kinases in cancer therapy
  Nature Reviews Drug Discovery, 2015
• The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
  The Lancet Oncology, 2015
• Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
  Journal of Clinical Investigation, 2011
• Triple-negative breast cancer: disease entity or title of convenience?
  Nature Reviews Clinical Oncology, 2010
• High prevalence of retinoblastoma protein loss in triple-negative breast cancers and its association with a good prognosis in patients treated with adjuvant chemotherapy
  Annals of Oncology, 2009
• The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas
  Breast Cancer Research, 2008
• The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes
  Clinical Cancer Research, 2007
• On-line complexation/cloud point preconcentration for the sensitive determination of dysprosium in urine by flow injection inductively coupled plasma–optical emission spectrometry
  Analytical and Bioanalytical Chemistry, 2002